ABVX.PA

Compare

No price history available for this symbol yet.

Fair-value model

Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.

Years of analysisAssumption entries

Analyst estimates unavailable for this ticker.

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Sector

Biotechnology

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$4M	-37.7%	$-3.29	$-3.91–$-2.75	—	4
2027	$101M	+2561.7%	$-3.13	$-4.10–$-2.18	—	3
2028	$441M	+335.2%	$-0.46	$-2.13–$0.40	—	3
2029	$1.1B	+153.8%	$4.88	$1.39–$15.60	—	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 3 of the last 7 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-05-22	$-0.80	$-0.61	+24.0%
2026-03-23	$-1.16	$-1.05	+9.5%
2025-12-15	$-0.68	$-2.10	-209.1%
2025-09-08	$-0.80	$-0.85	-6.1%
2025-03-24	$-1.46	$-1.50	-2.9%
2024-09-09	$-1.37	$-1.30	+5.3%
2024-04-02	$-0.85	$-1.79	-110.8%

DCF fair valuemodel estimate

Intrinsic value

$6.60

Price

$99.65

Implied downside

-93%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
ABVX.PAAbivax S.A.	$99.65	-1.63%	$8.7B	—
ABNX.PAABIONYX Pharma S.A.	$1.69	-8.15%	$71M	—
DBV.PADBV Technologies S.A.	$2.15	+2.38%	$363M	—
GNRO.PAGeNeuro S.A.	$0.03	+0.00%	$911562	—
IPH.PAInnate Pharma S.A.	$1.57	-1.26%

Abivax S.A.

Abivax S.A. is a Paris-based pharmaceutical firm, established in 2013, dedicated to identifying and refining treatments for various serious conditions, including inflammatory and infectious diseases, as well as cancer. Its primary drug candidate, ABX464, is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's disease, and COVID-19, and is in Phase IIa trials for rheumatoid arthritis. This compound has also successfully completed a Phase IIa study focused on achieving viral remission in HIV patients. Additionally, the company is advancing ABX 196, an immune-enhancing agent, through Phase 1/2 clinical trials for hepatocellular cancer. Beyond these main programs, Abivax is also engaged in research initiatives targeting Dengue fever, influenza, and the respiratory syncytial virus. The company holds significant licensing agreements with esteemed institutions such as the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie.

www.abivax.com

Employees: 80
IPO / List date: Jun 26, 2015
HQ: FR

Held by traders on TradeandTell

No one on the platform currently holds ABVX.PA.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in ABVX.PA as of their last filing.

Insider activity (SEC Form 4)

No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded ABVX.PA yet.